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Essentials
• CpG oligodeoxynucleotide (ODN) immuotherapeutics cause undesired platelet activating effects.
• It is crucial to understand the mechanisms of these effects to identify protective strategies.
• CpG ODN-induced platelet activation depends on C-type lectin-like receptor 2 (CLEC-2) and P2Y12.
• Targeting CLEC-2 or P2Y12 fully prevents CpG ODNinduced platelet activation and thrombosis.
Summary. Background: Synthetic phosphorothioate-modified CpG oligodeoxynucleotides (ODNs) show potent immunostimulatory properties that are widely exploited in clinical trials of anticancer treatment. Unexpectedly, a recent study indicated that CpG ODNs activate human platelets via the immunoreceptor tyrosine-based activation motif (ITAM)-coupled receptor glycoprotein VI. Objective: To further analyze the mechanisms of CpG ODNinduced platelet activation and identify potential inhibitory strategies. Methods: In vitro analyses were performed on human and mouse platelets, and on cell lines expressing platelet ITAM receptors. CpG ODN platelet-activating
Introduction
Nuclease-resistant phosphorothionate (PT) oligonucleotides bearing unmethylated CpG motifs, in which one of the oxygen atoms of the phosphate backbone is replaced by sulfur, are commonly used as bacterial DNA mimetics that show potent immunostimulatory properties. Preclinical studies, conducted in rodents and primates, and human clinical trials have demonstrated that CpG oligodeoxynucleotides (ODNs) significantly improve vaccine-specific antibody responses [1] . Numerous human clinical trials have been conducted for applications ranging from vaccine adjuvants to immunotherapies for allergy, cancer, and infectious diseases [2, 3] . Combining CpG ODNs with mAb therapy, chemotherapy or radiation therapy has proven beneficial in anticancer treatment [4] . Notably, intratumoral co-delivery of vaccines with CpG ODNs improves the immunotherapy of cancer [5, 6] . CpG ODN recognition by immune cells depends on the interaction of CpG ODNs with intracellular Toll-like receptor (TLR) 9 and subsequent stimulation of the myeloid differentiation primary response 88 (MyD88) signaling cascade [7] . The complex immunologic responses to CpG ODNs of various immune cell subsets involve both direct and indirect effects, resulting in the activation of natural killer cells, T cells, B cells, monocytes, macrophages, and dendritic cells [1, 8] .
Because of their therapeutic potential, synthetic PT-modified CpG ODNs belonging to at least three classes, A, B, and C, have been well characterized in preclinical studies. Among them, type B CpG ODNs have been the most extensively studied as potential immunotherapeutics in clinical trials [5, 9] . However, their impacts on platelet function have long been elusive. A recent study indicated that type C CpG ODNs activate platelets [10] . It was shown that platelet activation depends on PT backbone modification of the oligonucleotides, and that it occurs independently of TLR9. On human platelets, it was reported that the collagen receptor glycoprotein (GP) VI bound the oligonucleotides, mediating their platelet-activating effects.
Improving our understanding of these unforeseen effects of CpG ODNs is of paramount importance in view of the use of these molecules in numerous clinical trials, especially in patients with cancer presenting with a high risk of thrombosis [11, 12] .
Our study was aimed at further investigating the mechanisms of platelet activation by the three main types of CpG ODN in order to identify potential protective strategies. We analyzed the effects of CpG ODNs on human and mouse platelets both in ex vivo studies and in a mouse model of thrombosis.
Materials and methods

Reagents and antibodies
CpG ODNs were from Invivogen (Toulouse, France). Type A (human, 2216; mouse, 1585), type B (human, 2006; mouse, 1826) and type C (2395) CpG ODNs were used. Cangrelor was provided by The Medicines Company (Parsippany, NJ, USA). Apyrase (grade I), forskolin, ADP and chemicals were from Sigma-Aldrich (St. Louis, MO, USA). LY294002 was from Biomol (Brussels, Belgium). Rhodocytin was purified from Calloselasma rhodostoma venom as previously described [13] . Cross-linked collagen-related peptide (CRP) was obtained from R. Farndale. The Sulfo-EGS cross-linking compound was from Pierce (Waltham, MA, USA).
Mice
All experimental protocols were approved by the Animal Ethical Committee of the University of Li ege (protocol numbers: 1390 and 1791) and performed in accordance with the European Community Guidelines (directive 2010/63/UE). Experiments were conducted on wild-type C57BL/6J mice purchased from Charles River (Saint Germain Nuelles, France). TLR9 and MyD88 knockout mice and littermates were a kind gift from S. Akira. All mice were housed under controlled specific pathogen-free conditions. Male mice aged 8-12 weeks were used in all experiments. In some experiments, clopidogrel (Sanofi) was administered orally (30 mg kg
À1
) for 2 days to inhibit P2Y12 receptor-mediated platelet activation. Platelet C-type lectin-like receptor 2 (CLEC-2) and GPVI deficiency was obtained by treating mice with INU-1 and JAQ-1 antibodies, respectively, as previously described [14, 15] . We confirmed GPVI deficiency on platelets isolated from JAQ-1-treated mice by using fluorescein isothiocyanate (FITC)-labeled rat anti-mouse GPVI antibody (clone JAQ-1; Emfret Analytics, Eibelstadt, Germany) or FITC-labeled rat IgG1j isotype control in flow cytometry. CLEC-2 deficiency on platelets from INU-1-treated mice was confirmed by western blotting with an antimouse CLEC-2 antibody (Goat Anti-Human/Mouse/Rat CLEC-2/CLEC1B Antigen Affinity-purified Polyclonal Antibody; R&D Systems, Minneapolis, MN, USA). Controls for deficiency were obtained by mouse injection with the corresponding IgG.
whole blood samples and washed platelets by measuring platelet surface markers, e.g. P-selectin (CD62P) exposure, fibrinogen binding, and levels of active integrin a IIb b 3 (PAC-1). Levels of platelet-monocyte and platelet-neutrophil aggregates were also analyzed in whole blood. In uptake experiments, FITC-conjugated CpG ODNs were incubated with washed platelets or whole blood for increasing periods of time. Samples (paraformaldehyde 1%) were analyzed on a FACSVerse flow cytometer with the FACSuite software (BD Biosciences, Erembodegem, Belgium).
Platelet surface protein cross-linking, immunoprecipitation, and western blotting Protein cross-linking on surfaces of non-stimulated or stimulated washed platelets was performed by incubation with 0.15 mmol L À1 Sulfo-EGS cross-linking reagent, as previously described [17] . CLEC-2 was immunoprecipitated from platelet lysates with a goat anti-human CLEC-2 antibody (R&D Systems); monomers and oligomers were detected by western blotting. Western blotting detection of total tyrosine-phosphorylated proteins, of tyrosine-phosphorylated immunoprecipitated Syk and phospholipase (PL) Cc2 or of Syk phosphorylated on residues 525/526 was performed as previously described [17] .
Cell lines: culture, transfection, and binding assays DT40 cells were transfected with pEF6-hCLEC-2, or pCDNA3-GPVI plus pEF6-FccR, as previously described [18] . 
Results
Synthetic type A, B and C CpG ODNs induce human platelet activation and aggregation
We compared the abilities of the three main types of CpG ODN to activate platelets in whole blood samples from a representative cohort of healthy volunteers (n = 17). Flow cytometry platelet activation assays indicated that type A, B and C CpG ODNs, used in the range of clinically relevant concentrations, induced P-selectin exposure, a IIb b 3 activation and fibrinogen binding on platelet surfaces ( Fig. 1A; Fig. S1 ). In terms of fibrinogen binding, levels of platelet activation were comparable to those obtained after stimulation with high concentrations of the GPVI agonist CRP or rhodocytin, an agonist of CLEC-2. Significant positive correlations were found between platelet responses to the three types of CpG ODN and between each of them and CRP or rhodocytin, indicating that these platelet responses increase in parallel, and are likely to be controlled by common factors (Fig. 1B) . In accordance with their ability to activate platelets in whole blood, the three types of CpG ODN also potently increased the percentages of platelet-neutrophil and platelet-monocyte aggregates (Fig. 1C) . Type A CpG ODN caused immediate aggregation of washed platelets, whereas the response to type B CpG ODN was delayed by~20 min. Type C CpG ODN did not induce the aggregation of washed platelets (Fig. 1D ). However, a 30-min preincubation of PRP with type C CpG ODN induced a full platelet aggregation response (Fig. 1D) . Thus, the three types of synthetic CpG ODN activate human platelets and induce their aggregation. In agreement with the study of Flierl et al. [10] , only PT-modified CpG ODNs showed platelet-activating effects (not shown).
CLEC-2 binds CpG ODNs
A previous study reported that type C CpG ODNs are progressively sequestered on platelet surfaces, with maximum sequestration being observed after 30 min of incubation [21] . To further assess CpG ODN uptake and study its relationship with platelet activation, we incubated FITC-conjugated CpG ODNs with washed platelets and performed simultaneous flow cytometry analysis of the time course of CpG ODN binding and P-selectin exposure, as well as super-resolution confocal microscopy. We found that CpG ODN uptake increased in a timedependent manner and reached a maximum after 15 min (CpG ODN type A; Fig. 2A ), at which time P-selectin exposure was the highest. After 5 min of incubation, we observed that~50% of platelets were positive for CpG ODNs, and that these platelets expressed P-selectin on their surfaces (Fig. S2) . CpG ODN signals remained elevated after 30 min. In whole blood, the mean percentage of CpG ODN-bound platelets reached 70.4% AE 17.9% (n = 3) after 30 min of incubation, whereas this value was > 99% in PRP or washed platelets, possibly because of capture of CpG ODNs by immune cells in whole blood samples. On dendritic cells and B cells, the multilectin receptor DEC-205 has been identified as a receptor for CpG ODNs, leading to their internalization to TLR9-containing compartments [22] . We tested the hypothesis that CLEC-2, another member of the C-type lectin domain-containing protein family, could be a platelet receptor for CpG ODNs. Using super-resolution confocal microscopy, we demonstrated platelet uptake (internalization) of the three CpG ODN types ( Fig. 2B ; Fig. S3 ; Video S1). Most interestingly, CpG ODN uptake was accompanied by internalization of CLEC-2 receptors (Fig. 2C ). To further investigate whether CLEC-2 directly binds CpG ODNs, the receptor was heterologously expressed in DT40 cells, and flow cytometry binding assays were performed. DT40 cells expressing CLEC-2 were selected by use of an anti-human CLEC-2 antibody (Fig. 3A) . As shown in Fig. 3B , the percentages of cells binding type B and type C CpG ODNs significantly increased upon CLEC-2 expression. These data indicate that CLEC-2 binds CpG ODNs. In agreement with the study of Flierl et al. [10] , we found that GPVI-FccR complexes heterologously expressed in DT40 cells bound type C CpG ODN (Fig. S4 ). In contrast, we could not detect any significant binding of type A or type B CpG ODN to GPVI.
A role for CLEC-2 in CpG ODN-induced activation and aggregation of human platelets
In addition to their ability to activate platelets, CpG ODNs induced irreversible aggregation of human platelets ( Fig. 1D ). In order to analyze the respective roles of CLEC-2 and GPVI in CpG ODN-induced platelet aggregation, we took advantage of the fact that phosphoinositide 3-kinase (PI3K) is essential for Syk activation and subsequent platelet aggregation downstream of CLEC-2, but not of GPVI [23] , and we compared the effects of the pan-PI3K inhibitor LY296002 on CpG ODN-induced, rhodocytin-induced and CRP-induced platelet aggregation (Fig. 4A) . These experiments were conducted with type A CpG ODN, which induced aggregation of washed platelets with similar kinetics as those of CRP and rhodocytin. LY296002 abolished the aggregation of human platelets induced by CpG ODNs or rhodocytin, whereas they only partially inhibited the response to CRP, suggesting that CpG ODNs could signal through CLEC-2 in platelets. We then preincubated human washed platelets with the blocking anti-human CLEC-2 antibody AYP1 or IgG control prior to the addition of CpG ODNs. AYP1 inhibited CpG ODNinduced and rhodocytin-induced platelet aggregation, whereas the platelet response to CRP was maintained (Fig. 4B) . Type A CpG ODN induced a pattern of tyrosine phosphorylation that was very similar to that induced by rhodocytin and CRP (Fig. 4C ). CLEC-2 dimerization is essential for Syk activation induced by rhodocytin [17] . In order to determine whether CpG ODNs cause CLEC-2 dimerization, we used the crosslinking reagent Sulfo-EGS, and assessed the formation of CLEC-2 dimers and oligomers by immunoprecipitation and western blotting. In the presence of CpG ODNs, Sulfo-EGS increased the formation of CLEC-2 dimers, and caused the disappearance of monomers (Fig. 4D) . In contrast to the efefct of rhodocytin, higher-order oligomers were, however, not detected. These data indicate that CLEC-2 mediates CpG ODNinduced activation and aggregation of human platelets.
Inhibition of P2Y12 receptor prevents CpG ODN effects CLEC-2-mediated platelet activation and aggregation involve the ADP and thromboxane A 2 -dependent amplification pathways [24] . We therefore assessed the role of these pathways in CpG ODN effects on platelets. Human platelets were pretreated with apyrase, an enzyme that degrades ATP and ADP, with the P2Y12 ADP receptor antagonist cangrelor, or with indomethacin, an inhibitor of thromboxane A 2 production. Apyrase and, to a lesser extent, indomethacin inhibited P-selectin exposure and fibrinogen binding on platelet surfaces induced by type A and type B CpG ODNs ( Fig. 5A; Fig. S5A ). P-selectin exposure was also potently inhibited by cangrelor (type C CpG ODN; Fig. S5B) . Notably, pretreating platelets with cangrelor significantly reduced the uptake of the three types of CpG ODN (Fig. S5C) . We then further evaluated the role of P2Y12 receptor in CpG ODN plateletactivating effects by using whole blood samples from five patients receiving clopidogrel therapy because of a distant acute coronary syndrome (> 3 months). Interestingly, platelets isolated from these patients did not react to CpG ODNs, as shown by the analysis of P-selectin exposure and fibrinogen binding, whereas they still reacted to CRP (Fig. 5B) . Results are shown for type A CpG ODN, but they also apply to type B and type C CpG ODNs (data not shown). Platelet aggregation induced by CpG ODNs was fully abrogated by clopidogrel therapy, but also by pretreating platelets of healthy volunteers with the P2Y12 antagonist cangrelor, or by apyrase (Fig. 5C ). It should be noticed that, in contrast to the CpG ODN response, rhodocytin-induced platelet aggregation is not significantly affected by apyrase alone [25] . In accordance with an important role for ADP in the platelet response to CpG ODNs, lumi-aggregometry recordings revealed that CpG ODNs caused ATP secretion that preceded the aggregation response (Fig. 5D) . Likewise, the delay before type C CpG ODN-induced aggregation was significantly shortened by the addition of a sub-aggregating dose of ADP (Fig. S6) . Furthermore, type A CpG ODN was able to reverse the inhibitory effect of forskolin on ADP-induced platelet aggregation (Fig. S7) . Altogether, these results show that P2Y12 is necessary to mediate the activation and aggregation of human platelets by the three CpG ODN types. Platelets may capture CpG ODNs via CLEC-2, causing platelet degranulation and subsequent P2Y12 activation, which reinforces CpG ODN uptake and platelet aggregation.
Major roles for CLEC-2 and P2Y12 in CpG ODN-induced activation of mouse platelets
In addition to the study of Flierl et al. [10] showing that GPVI mediates the activation of human platelets by type C CpG ODN, our data provide evidence for major roles of CLEC-2 and P2Y12 receptors. In order to obtain more insight into the respective contributions of these platelet receptors, we generated GPVI-deficient and CLEC-2-deficient mouse platelets by treating the mice with the JAQ1 and INU1 antibodies, respectively. Other mice were treated with clopidogrel to inhibit P2Y12. We found that type C CpG ODN caused activation of control mouse platelets in washed platelet preparations and whole blood, whereas type A CpG ODN was only active on washed platelets, and type B CpG ODN failed to activate mouse platelets (Fig. S8) . CLEC 2 deficiency and P2Y12 inhibition abrogated both P-selectin exposure, a IIb b 3 activation and platelet aggregation induced by type C CpG ODN (Fig. 6A,B) and CpG ODN uptake (Fig. 6C) . In sharp contrast, GPVI-depleted mouse platelets still captured the ODNs, and showed only partial inhibition of P-selectin exposure and a delay of aggregation ( Fig. 6A-C) . Platelet responses to type A CpG ODN were similarly inhibited by CLEC-2 deficiency or P2Y12 inhibition (data not shown). As expected, GPVI-deficient, CLEC-2-deficient and P2Y12-deficient platelets failed to aggregate in response to CRP, rhodocytin, and ADP, respectively (Fig. 6A) . CpG ODN-induced total and Syk tyrosine phosphorylation were fully inhibited upon ) are also given. Data represent mean AE standard deviation (SD) (n = 3-5). *P < 0.05 and **P < 0.01 versus control. (B) Flow cytometry analysis of P-selectin exposition and fibrinogen binding on platelets isolated from control mice, JAQ1-treated mice, INU-1-treated mice or clopidogreltreated mice upon stimulation with CpG ODNs (10 lmol L À1 ). Data represent mean AE SD (n = 3-13). **P < 0.01 and ***P < 0.001 versus CLEC-2 depletion (Figure S9A,B) . P2Y12 inhibition with ticagrelor also abrogated the tyrosine phosphorylation of Syk and PLCc2 elicited by CpG ODNs (Fig. S9C) . Finally, the use of platelets isolated from TLR9-deficient and MyD88-deficient mice confirmed that CpG ODNs induced mouse platelet aggregation independently of TLR9 or TLR signaling (Fig. S10) . Thus, similarly to what is seen in humans, our data show major roles for CLEC-2 and P2Y12 in CpG ODN uptake, and subsequent activation and aggregation of mouse platelets.
P2Y12 inhibition or CLEC-2 deficiency prevents CpG ODN-elicited thrombosis in mice
We then assessed whether intravenously injected type C CpG ODN, at immunotherapeutic doses, could impact on thrombus formation, and whether this could be counteracted by targeting CLEC-2 or P2Y12. We used a model of laser-induced injury of the arterioles of the mouse cremaster muscle, and monitored platelet accumulation at the site of injury. Signals of FITC-conjugated CpG ODNs were also recorded. As shown in Fig. 7A ,B, platelet accumulation was strongly enhanced in the presence of CpG ODNs, but was fully inhibited by CLEC-2 deficiency or by inhibiting P2Y12 with clopidogrel therapy. Also, these experiments showed that CpG ODNs rapidly accumulated at the site of injury, and were progressively incorporated into the growing thrombi ( Fig. 7C ; Video S2). Accordingly, CpG ODN signals at the site of injury were no longer augmented upon treatment with clopidogrel.
Discussion
We demonstrate platelet uptake of type A, B and C CpG ODNs, leading to subsequent platelet activation and aggregation. In vivo, CpG ODNs accumulate at sites of endothelial injury and are incorporated into growing thrombi, promoting thrombosis. We identified CLEC-2 as a platelet receptor for CpG ODNs on mouse and human platelets, and we showed that P2Y12 is necessary to mediate CpG ODN uptake, platelet activation, and platelet aggregation. Furthermore, we found that CLEC-2 deficiency or inhibition of P2Y12 receptors abolished CpG ODN-induced platelet activation and aggregation, and prevented the CpG ODN prothrombotic effect. Our study goes far beyond the work of Flierl et al. [10] , who showed that type C CpG ODNs activate human platelets through the collagen receptor GPVI. In their work, pulldown experiments with GPVI-Fc and beads coated with type C CpG ODN revealed that these ODNs directly interact with GPVI. We confirmed that GPVIFccR complexes heterologously expressed in DT40 cells bind type C CpG ODNs, but we further showed that CLEC-2 binds types A, B and C CpG ODNs. We provide several pieces of evidence for major roles of platelet receptors other than GPVI in the response of human platelets to CpG ODNs: (i) type A CpG ODN caused CLEC-2 receptor dimerization and its internalization; (ii) P2Y12 inhibition by clopidogrel, or the ADP scavenger apyrase, potently inhibited P-selectin exposure and fibrinogen binding induced by all types of CpG ODN; and (iii) CLEC-2 inhibition by the blocking antibody AYP1, apyrase, P2Y12 inhibitors or inhibition of PI3K signaling prevented type A CpG ODN-induced platelet aggregation, but did not affect responses to CRP. The use of CLEC-2-depleted and GPVI-depleted mouse platelets, and of platelets from clopidogrel-treated mice, allowed us to confirm the role of CLEC-2 and P2Y12 receptors in CpG ODN uptake, and in subsequent platelet P-selectin exposure, a IIb b 3 activation, and platelet aggregation. In sharp contrast, GPVI-depleted platelets only showed partial inhibition of P-selectin exposure and a delayed aggregation response, possibly indicating interspecies differences.
Thus, CLEC-2 and P2Y12 are instrumental in mediating the activation of both mouse and human platelets by CpG ODNs, whereas GPVI is dispensable in mice. CLEC-2 is a non-classic C-type lectin [26] . It has a cytoplasmic tail of 31 amino acids containing a single YxxL motif (referred to as hem-immunoreceptor tyrosine-based activation motif). CLEC-2 is highly and specifically expressed in platelets and megakaryocytes [27, 28] . Our finding that CLEC-2 mediates mouse platelet activation and aggregation induced by CpG ODN is compatible with studies in mice showing an important role for this receptor in thrombus formation and stabilization, and in the prevention of inflammatory bleeding [15, 29, 30] . CLEC-2 elicits powerful platelet activation signals via Src and Syk kinase-dependent tyrosine phosphorylation events, ultimately leading to PLCc2 activation [17] . The ability of CpG ODNs to activate the tyrosine kinase pathway is consistent with our observation that these ODNs cause CLEC-2 dimerization, which is required for Syk activation [17] . Nevertheless, we observed differences between the effects of CpG ODNs and those of the CLEC-2 agonist rhodocytin. We indeed found that CpG ODN-induced Syk and PLCc2 phosphorylation and platelet aggregation were fully inhibited by apyrase or P2Y12 antagonism, whereas these treatments did not affect rhodocytin responses. Our findings in DT40 cells expressing CLEC-2 indicate that this receptor binds CpG ODNs, and could therefore be involved in their uptake by platelets. The fact that CpG ODN-induced platelet activation is strongly inhibited by pretreating platelets with apyrase, an ADP/ATP scavenger, or with P2Y12 inhibitors indicates a major role for secreted ADP and P2Y12, which is in contrast to the effects of rhodocytin [24, 25] . We found that CpG ODNs caused rapid ATP secretion that preceded the start of the aggregation response. Our findings support a cascade of events during which CLEC-2 binds to CpG ODNs, triggering platelet degranulation and activation of the P2Y12 ADP receptor. P2Y12 receptor is then necessary to reinforce CpG ODN uptake, PI3K-dependent tyrosine phosphorylation, and subsequent platelet activation, leading to platelet aggregation. Moreover, the observed platelet uptake of CpG ODNs could occur through CLEC-2 internalization [31] . By analogy, in immune cells, another C-type lectin receptor, DEC-205, was shown to be critical for the capture of CpG ODNs that is required for intracellular TLR9 stimulation and optimal adjuvancy effects of type B CpG ODNs [22] . In contrast to what is seen in immune cells, we found that CpG ODNs cause platelet activation independently of TLR9, which suggests that, in platelets, CpG ODN uptake might serve a function other than delivering nucleic acids to TLR9. As for many C-type lectin receptors, the domain structure of CLEC-2 is compatible with a potential for recognition of multiple ligands. The recent crystallization of podoplanin-CLEC-2 and rhodocytin-CLEC-2 complexes revealed that CLEC-2 can utilize all surfaces as potential sites for unidentified endogenous and exogenous ligands, which may include those originating from microorganisms, and employ different dimer conformations to achieve effective signaling [32] . The structural frames of C-type lectin receptors seem to be beneficial for detecting various types of ligand, which probably play a key role in host defense [33] . In this context, a recent study in mice showed a role for CLEC-2 in liver thrombosis elicited upon systemic infection with Salmonella typhimurium [34] . It is tempting to speculate that CLEC-2-mediated platelet activation by bacterial DNA could also contribute to infection-related thrombosis. This would be in line with the recent concept that platelets represent rapid first-line immune responders [35] .
In conclusion, our study further demonstrates and provides mechanistic insights into CpG ODN platelet-activating and prothrombotic effects. Although the clinical importance of these effects still needs to be evaluated in large clinical studies, thrombosis events have already been reported both in clinical trials using type B CpG ODN (portal vein thrombosis) [36] and in preclinical animal models [37, 38] . Despite the clinical benefits of using CpG ODNs for the treatment of cancer, infectious diseases, and allergic diseases, thrombotic risk must be taken into account in the future design of therapeutic CpG ODNs. This phenomenon could be exacerbated in pathologic conditions such as cancer, which is often associated with the production of hyper-reactive platelets [12] . Importantly, our study shows that the inhibition of P2Y12 receptors with clinically available antiplatelet drugs may confer protection against possible adverse prothrombotic effects of CpG ODNs. 
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Supporting Information
Additional Supporting Information may be found in the online version of this article: Fig. S1 . Flow cytometric analysis of levels of active a IIb b 3 integrin (using PAC-1 antibody) expressed on platelet surface upon 30 min of incubation of citrated human whole blood with 10 lmol L À1 CpG ODNs. Box-and-whisker plots are shown. *P < 0.05, ***P < 0.001 versus non stimulated (NS). Fig. S2 . Flow cytometric analysis of P-selectin expression on surfaces of human washed platelets upon incubation with FITC-conjugated CpG ODN type A for increasing times. Fig. S3 . Super-resolution confocal microscopy images (9 2400) of human washed platelets after 30 min of incubation with FITC-conjugated CpG ODN type B or C (10 lmol L À1 ), as indicated. 
